Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR) under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
Key transaction details include:
- Transaction Date: Notification issued on April 16, 2014, following a dividend payment on April 10, 2014.
- Share Price: 1,581.50 pence per Ordinary Share; $52.55 per American Depositary Share (ADS).
- Transaction Type: Notional increases in share interests resulting from the re-investment of dividends.
Material Changes
The filing details specific increases in notional shareholdings for various directors and PDMRs. Notable increases include:
- Sir Andrew Witty: 19,564.837 Ordinary Shares
- Dr P J T Vallance: 8,136.668 Ordinary Shares
- Mr S Dingemans: 8,217.586 Ordinary Shares
- Dr M M Slaoui: 5,637.905 Ordinary Shares
The filing does not provide comparative data against prior periods for these specific notional holdings.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share plan activity in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the vesting schedule and measurement period for the 2009 Performance Share Plan to understand when notional dividends become payable.
- Confirm the total number of Ordinary Shares and ADSs held by each director following this notional re-investment.
- Review the dividend payment details for April 10, 2014, to validate the basis for the notional re-investment.